Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg Independent dataset from EAP reinforces the ...

aGvHD is a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. The patients (N=173) treated in EAP previously failed 1 to 6 aGvHD systemic treatment ...

Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013. Poster presentation selected for ongoing ...

Enrollment milestone and ongoing study to be highlighted at SAWC Fall 2025; Merakris expanding clinical trial site partnershipsRESEARCH TRIANGLE PARK, N.C, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Merakris ...

NeXT Personal Dx is an ultra-sensitive test for detecting cancer from a blood sample Clinical data from groundbreaking TRACERx lung cancer study demonstrates significant sensitivity and lead time ...

The FDA has authorized the Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and therapeutic agent MNPR-101-Lu, allowing patients with advanced solid tumors access to ...

San Jose, Calif. August 28, 2012—Altera Corporation (Nasdaq: ALTR) today announced its OpenCL (Open Computing Language) for FPGAs Early Access Program (EAP), enabling customers to get a first look ...

Merakris Therapeutics, a regenerative medicine company developing biologically derived therapeutics, announced the enrollment of the 30th subject in its Expanded ...